18F-FDG PET imaging-monitored anti-inflammatory therapy for acute myocardial infarction: Exploring the role of MCC950 in murine model

• Published in: Journal of nuclear cardiology Vol. 28; no. 5; pp. 2346 - 2357
• Main Authors: Li, Xiang, Yang, Weidong, Ma, Wenhui, Zhou, Xiang, Quan, Zhiyong, Li, Guoquan, Liu, Daliang, Zhang, Qingju, Han, Dong, Gao, Beilei, Li, Congye, Wang, Jing, Kang, Fei
• Format: Journal Article
• Language: English
• Published: Cham Elsevier Inc 01.10.2021; Springer International Publishing; Springer Nature B.V
• Subjects: 18F-FDG PET imaging; Acute myocardial infarction (AMI); Cardiology; Heart attacks; Imaging; Inflammation; MCC950; Medicine; Medicine & Public Health; Nuclear Medicine; Original Article; Radiology; TTC; BGL; LVEF; 18F-FDG; Acute myocardial infarction (AMI); IL-1β; WGA; ID/g; MCC950; inflammation; 18F-FDG PET imaging; NLRP3; AMI; PET; F-FDG PET imaging
• ISSN: 1071-3581; 1532-6551
• DOI: 10.1007/s12350-020-02044-0

MCC950 is a novel NLRP3 inflammasome inhibitor that possesses potent anti-inflammatory properties in acute myocardial infarction (AMI). However, the lack of noninvasive monitoring methods limits its potential clinical translation. Thus, we sought to investigate whether 18F-FDG PET imaging can monitor the therapeutic effects of MCC950 in an AMI murine model. C57BL/6 mice were used to generate an AMI model. MCC950 or sterile saline was intraperitoneally administered 1 hour after surgery and then daily for 7 consecutive days. 18F-FDG PET (inflammation) imaging was used to monitor inflammatory changes on days 3 and 5. Immunohistochemistry and Western blot were used to detect inflammatory markers and to confirm the PET imaging results. 18F-FDG PET (viability) imaging was used to quantitate the viability defect expansion on days 7 and 28. Cardiac ultrasound and survival analyses were performed to evaluate the cardiac function and survival rate. Adverse remodeling was determined by Wheat Germ Agglutinin (WGA) and Masson trichrome staining. The FDG-PET (inflammation) imaging revealed that MCC950 treatment led to lower 18F-FDG inflammatory uptakes, at the infarct region, on days 3 and 5 when compared to the MI group. The decreased M1 macrophages and neutrophils infiltration and the remission of the NLRP3/IL-1β pathway, confirmed the FDG-PET (inflammation) imaging results. The FDG-PET (viability) imaging revealed that MCC950 significantly decreased the expansion of the viability defect, demonstrating its myocardial preservation effects. The acute FDG-PET (inflammation) signal positively correlated with the late viability defect and with the reduction in the left ventricular ejection fraction (LVEF). Additionally, the alleviated adverse remodeling and the improved survival rate further support the anti-inflammatory efficiency of MCC950 in AMI. Using 18F-FDG PET imaging, we noninvasively demonstrated the therapeutic effects of MCC950 in AMI and showed that 18F-FDG PET imaging holds promising application potentials in MCC950’s clinical translation.